Bibliography
- Soderling SH, Bayuga SJ, Beavo JA, Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci USA 1999;96(12):7071-6
- Fujishige K, Kotera J, Michibata H, Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 1999;274(26):18438-45
- Loughney K, Snyder PB, Uher L. Isolation and characterization of PDE10A, a novel human 3′, 5′-cyclic nucleotide phosphodiesterase. Gene 1999;234(1):109-17
- Coskran TM, Morton D, Menniti FS Immuno-histochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem 2006;54(11):1205-13
- Hebb AL, Robertson HA, Denovan-Wright EM, Striatal phosphodiesterase mRNA and protein levels are reduced in huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience 2004;123(4):967-81
- Giampà C, Patassini S, Borreca A, Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of huntington's disease. Neurobiol Dis 2009;34(3):450-6
- Siuciak JA, Chapin DS, Harms JF. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 2006;51(2):386-96
- Siuciak JA, McCarthy SA, Chapin DS, Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function. Neuropharmacology 2006;51(2):374-85
- Menniti FS, Chappie TA, Humphrey JM, Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Invest Drugs 2007;8(1):54-9
- Schmidt CJ, Chapin DS, Cianfrogna J, Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 2008;325(2):681-90
- Weber M, Breier M, Ko D, Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine. Psychopharmacology 2009;203(4):723-35
- Siuciak JA. The role of phosphodiesterases in schizophrenia. CNS Drugs 2008;22(12):983-93
- Grauer SM, Pulito VL, Navarra RL, PDE10A inhibitor activity in preclinical models of the positive, cognitive and negative symptoms of schizophrenia. J Pharmacol Exp Ther 2009; DOI:10.1124/jpet.109.155994
- Chappie T, Humphrey J, Menniti F, PDE10A inhibitors: an assessment of the current CNS drug discovery landscape. Curr Opin Drug Discov Devel 2009;12(4):458-67
- Wang H, Liu Y, Hou J, Structural insight into substrate specificity of phosphodiesterase. Proc Natl Acad Sci USA 2007;104(14):5782-7
- Card GL, England BP, Suzuki Y, Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure (Cambridge) 2004;12:2233-47
- Manallack DT, Hughes RA, Thompson PE. The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J Med Chem 2005;48:3449-62
- Gross-Langenhoff M, Hofbauer K, Weber J, cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11. J Biol Chem 2006;281(5):2841-6
- Handa N, Mizohata E, Kishishita S, Crystal structure of the GAF-B domain from human phosphodiesterase 10A complexed with its ligand, cAMP. J Biol Chem 2008;283(28):19657-64
- Chappie TA, Humphrey JM, Allen MP, Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors. J Med Chem 2007;50(2):182-5
- Verhoest PR, Chapin DS, Corman M, Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem 2009;52(16):5188-96
- F.Hoffmann-LA. ROCHE AGWO 2009/090004; 2009
- Wadenberg MLG, Hicks PB. The conditioned avoidance response test re-evaluated: Is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 1999;23(6):851-62
- Sano H, Nagai Y, Miyakawa T, Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2. J Neurochem 2008;105(2):546-56
- Elbion AG. WO-2007137819; 2007
- Elbion AG. WO-2007137820; 2007
- Wyeth/Elbion AG. WO 2009/068246; 2009
- Elbion AG. WO 2009/068320; 2009
- Wyeth/Elbion AG. WO 2009/070583; 2009
- Wyeth/Elbion AG. WO 2009/070584; 2009
- Malamas MS, Hoefgen N, Stange H, Potent and selective hPDE10A inhibitors for the treatment of schizophrenia. Abstracts of Papers, 238th ACS National Meeting, Washington, DC, United States, August 16-20; 2009, MEDI-021
- Pfizer, Inc. WO2007085954; 2007
- Pfizer, Inc. WO2007096743; 2007
- Pfizer, Inc. WO2008020302; 2008
- Pfizer, Inc. US20070155779; 2007
- Pfizer, Inc. WO2008001182; 2008
- Pfizer, Inc. WO2008004117; 2008
- Pfizer, Inc. WO2008084299; 2008
- H Lundbeck A/S. WO2007082546; 2007
- H Lundbeck A/S. WO2008006372; 2008
- H Lundbeck A/S. WO2009036766; 2009
- Amgen Inc; Memory Pharmaceuticals Corp. WO2007022280; 2007
- Amgen Inc; Memory Pharmaceuticals Corp. WO2007098169; 2007
- Amgen Inc; Memory Pharmaceuticals Corp. WO2007098214; 2007
- Amgen Inc; Memory Pharmaceuticals Corp. WO2007100880; 2007
- Amgen Inc; Memory Pharmaceuticals Corp. WO2007103554; 2007
- Amgen Inc; Memory Pharmaceuticals Corp. WO2007103370; 2007
- Amgen Inc; Memory Pharmaceuticals Corp. WO2007103260; 2007
- Amgen Inc; Memory Pharmaceuticals Corp. WO2009025823 and WO2009025839; 2009
- Amgen Inc; Memory Pharmaceuticals Corp. WO2009029214; 2009
- Matrix Laboratories Ltd. WO2008032171; 2008
- Omeros Corp. WO2008064342; 2008
- OmerOs Corp101. US20080300240; 2008